Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

gedeon richter plc., maďarsko - dabigatránetexilát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - dabigatránetexilát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - dabigatránetexilát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - dabigatránetexilát - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Unione Europea - slovacco - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner, milbemycin oxime - endectocides, antiparazitické prípravky, insekticídy a repelenty, milbemycin oxime, kombinácie - psy - na liečbu velká a zaškrtnite škodcami v psov pri súčasnom zabránení heartworm ochorenia (dirofilaria immitis larvy), angiostrongylosis (zníženie úrovne nezrelé dospelých (l5) a dospelých angiostrongylus vasorum), thelaziosis (pre dospelých thelazia callipaeda) a/alebo liečba gastrointestinálnych borovicové hmyzom je uvedené. liečba velká hmyzom (ctenocephalides felis a c. canis) v psov na 5 týždňov. liečba kliešť hmyzom (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus) v psov pre 4 týždňov. blechy a kliešte sa musia pripojiť k hostiteľovi a začať kŕmiť, aby boli vystavení účinnej látke. liečba napadnutia s dospelými gastrointestinálne háďatká z nasledujúcich druhov: roundworms (toxocara canis a toxascaris leonina), hookworms (ancylostoma caninum, ancylostoma braziliense a ancylostoma ceylanicum) a whipworm (trichuris vulpis). liečba demodicosis (spôsobené demodex canis). liečba sarcoptic mange (spôsobené sarcoptes scabiei var. canis). prevencia heartworm ochorenia (dirofilaria immitis lariev) mesačné správy. prevencia angiostrongylosis (redukciu úrovne infekcie s nezrelé dospelých (l5) a dospelých štádií angiostrongylus vasorum) mesačné správy. prevencia vzniku thelaziosis (pre dospelých thelazia callipaeda eyeworm infekcie) mesačné správy.

Unione Europea - slovacco - EMA (European Medicines Agency)

eco animal health europe limited - tylvalozín - antiinfektíva na systémové použitie, antibakteriálne pre systémové použitie, macrolides - pheasants; chicken; turkeys; pigs - pigstreatment a methaphylaxis svíň enzootic zápal pľúc;ošetrovanie ošípaných proliferatívne enteropatia (ileitis), liečba a methaphylaxis svíň úplavica. chickenstreatment a methaphylaxis respiračných ochorení spojených s mycoplasma gallisepticum v kurčiat. pheasantstreatment respiračných ochorení spojených s mycoplasma gallisepticum. turkeystreatment respiračných ochorení spojených s tylvalosin citlivé kmene ornithobacterium rhinotracheale v morky.

Unione Europea - slovacco - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimykotika na systémové použitie - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invázne aspergillosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo itraconazole alebo u pacientov, ktorí netolerujú týchto liekov;- fusariosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo u pacientov, ktorí netolerujú z amphotericin b;- chromoblastomycosis a mycetoma u pacientov s ochorením, ktoré je žiaruvzdorných na itraconazole alebo u pacientov, ktorí netolerujú z itraconazole;- kokcidiomykóza u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b, itraconazole alebo fluconazol alebo u pacientov, ktorí netolerujú týchto liekov;- oropharyngeal kandidóza: ako v prvej línii liečby u pacientov, ktorí majú závažné ochorenie alebo sú imunokompromitovaných, v ktorých reakcie na aktuálne terapia sa očakáva, že byť chudobným. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Unione Europea - slovacco - EMA (European Medicines Agency)

actavis group ptc ehf   - monohydrát kyseliny zoledrónovej - zlomeniny, kosti - lieky na liečbu chorôb kostí - prevencia príhod súvisiacich so skeletom (patologické zlomeniny, kompresia miechy, žiarením alebo chirurgický zákrok na kosti, alebo hyperkalciémia vyvolaná nádorom) u dospelých pacientov s pokročilým nádorovým ochorením kostnej. liečba dospelých pacientov s nádor vyvolaných hypercalcaemia.

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ratiopharm gmbh, nemecko - simvastatín - 31 - hypolipidaemica

Slovacchia - slovacco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ratiopharm gmbh, nemecko - simvastatín - 31 - hypolipidaemica